Biologic medications are recent advances that have clinical significance in the 
treatment of moderate-to-severe AD. A systemic literature review was performed 
to examine the efficacy and safety of biologic therapies currently in phase II 
and phase III of clinical trials for moderate-to-severe AD. Our team searched 
the databases, PubMed, Google Scholar, and ClinicalTrials.gov, on September 2019 
for studies pertaining to the use of biologic drugs in AD. Key words included 
each drug (lebrikizumab, tralokinumab, fezakinumab, etokimab, nemolizumab, 
tezepelumab, and GBR 830) or 'biologic drugs' or 'immunotherapies' combined with 
'atopic dermatitis.' References within retrieved articles were also reviewed to 
identify potentially missed studies. A total of 19 articles were included in 
this review. Lebrikizumab, tralokinumab, fezakinumab, nemolizumab, and GBR 830 
lead to statistically significant improvements in disease severity and multiple 
endpoint outcome scores. Tezepelumab and etokimab, however, did not demonstrate 
statistically significant changes in primary outcome endpoints. Further 
assessment of tezepelumab and etokimab are needed to assess their safety and 
efficacy in patients with moderate-to-severe AD. Tralokinumab, lebrikizumab, 
fezakinumab, nemolizumab, and GBR 830 are effective treatment options for adults 
with moderate-to-severe AD, but further large-scale studies are needed to 
confirm their efficacy as monotherapy in children with moderate-to-severe AD.